Minimal residual disease (MRD) is the most important independent prognostic factor in acute lymphoblastic leukemia (ALL). Since it has been implemented into in treatment stratification strategies, cure rates have improved significantly for all age groups. Real time quantitative (RQ)-PCR of clonal immunoglobulin and T-cell receptor gene rearrangements using allele-specific primers is currently regarded as the gold standard for MRD analysis in ALL, as it is not only highly sensitive and specific but also provides accurate MRD quantification. Following recent advances in next-generation sequencing (NGS), much attention has been devoted to the development of NGS-based MRD assays. This new technique can enhance sensitivity provided that sufficient numbers of cells are analyzed. Recent reports have shown that NGS-MRD also tends to be more specific for relapse prediction than RQ-PCR. In addition, NGS provides information on the physiological B- and T-cell repertoire during and after treatment, which has been shown to be prognostically relevant. However, before implementation of NGS-MRD detection in clinical practice, several issues must be addressed and the whole workflow needs to be standardized, including not only the analytical phase (spike-in calibrators, quality controls) but also the pre-analytical (e.g. sample preparation) and the post-analytical phases (e.g. bioinformatics pipeline, guidelines for correct data interpretation). These topics are currently addressed by a European network, the EuroClonality-NGS Consortium. In conclusion, NGS is a promising tool for MRD detection with the potential to overcome most of the limitations of RQ-PCR and to become the new gold standard for MRD detection in ALL.

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University University Hospital Motol Prague Czech Republic

Department of Hematology University of Schleswig Holstein Campus Kiel Langer Segen 8 10 24105 Kiel Germany

Zobrazit více v PubMed

Haematologica. 2007 May;92(5):612-8 PubMed

Leukemia. 2014 Jun;28(6):1299-307 PubMed

Leukemia. 1999 Jan;13(1):110-8 PubMed

Leukemia. 2002 Sep;16(9):1668-72 PubMed

Methods Mol Biol. 2012;882:569-604 PubMed

Haematologica. 2017 Feb;102(2):e57-e60 PubMed

Bone Marrow Transplant. 2017 Apr;52(4):544-551 PubMed

Bone Marrow Transplant. 2008 Aug;42(3):187-96 PubMed

Br J Haematol. 2003 Nov;123(3):561-2 PubMed

Methods Mol Biol. 2009;538:115-50 PubMed

Front Immunol. 2016 Sep 09;7:339 PubMed

Sci Transl Med. 2016 Nov 9;8(364):364ra155 PubMed

Blood. 2008 Jun 15;111(12):5477-85 PubMed

Genome Res. 1996 Oct;6(10):986-94 PubMed

N Engl J Med. 2013 Apr 18;368(16):1509-1518 PubMed

Nucleic Acids Res. 2015 Jan;43(Database issue):D413-22 PubMed

Leukemia. 2012 Sep;26(9):1908-75 PubMed

Genes Chromosomes Cancer. 2012 Jul;51(7):689-95 PubMed

J Clin Oncol. 2002 Feb 15;20(4):1094-104 PubMed

Leukemia. 2008 Mar;22(3):641-4 PubMed

Nat Med. 2013 Mar;19(3):368-71 PubMed

Blood. 2002 Jul 1;100(1):52-8 PubMed

Leukemia. 1998 Dec;12(12):2006-14 PubMed

Pediatr Blood Cancer. 2007 Jan;48(1):93-100 PubMed

J Clin Oncol. 2014 Feb 20;32(6):579-86 PubMed

PLoS One. 2014 Apr 10;9(4):e94249 PubMed

Ann Hematol. 2004;83 Suppl 1:S129-31 PubMed

Lancet Oncol. 2015 May;16(5):541-9 PubMed

Cancer. 2010 Mar 1;116(5):1165-76 PubMed

Lancet. 2001 Oct 13;358(9289):1239-41 PubMed

Clin Chim Acta. 1991 Apr;198(1-2):1-91 PubMed

Nat Methods. 2013 Sep;10(9):813-4 PubMed

PLoS One. 2016 Nov 11;11(11):e0166126 PubMed

Biol Blood Marrow Transplant. 2014 Sep;20(9):1307-13 PubMed

Blood. 2002 Apr 1;99(7):2315-23 PubMed

Eur J Cancer Care (Engl). 2005 Mar;14(1):53-62 PubMed

Br J Haematol. 2009 Jan;144(1):107-15 PubMed

Leukemia. 2007 Apr;21(4):604-11 PubMed

Neth J Med. 1987 Dec;31(5-6):201-9 PubMed

Leukemia. 2008 Apr;22(4):771-82 PubMed

Bioinformatics. 2017 Feb 1;33(3):435-437 PubMed

Leukemia. 2007 Apr;21(4):622-6 PubMed

Blood. 2012 Nov 29;120(23):4470-81 PubMed

Blood. 2012 Dec 20;120(26):5173-80 PubMed

Blood. 2002 Feb 15;99(4):1253-8 PubMed

Nat Commun. 2013;4:2680 PubMed

Sci Transl Med. 2016 Jul 6;8(346):346ra92 PubMed

Sci Transl Med. 2012 May 16;4(134):134ra63 PubMed

Lancet Oncol. 2013 Mar;14 (3):199-209 PubMed

N Engl J Med. 1998 Aug 27;339(9):591-8 PubMed

Br J Haematol. 2016 May;173(3):413-20 PubMed

Leukemia. 2004 Mar;18(3):499-504 PubMed

Blood. 2017 Jan 19;129(3):347-357 PubMed

Blood. 2006 Feb 1;107(3):1116-23 PubMed

Leukemia. 2012 Sep;26(9):1986-2010 PubMed

Leukemia. 2003 Dec;17(12):2257-317 PubMed

Blood. 2012 Sep 6;120(10):2032-41 PubMed

Lancet. 1998 Nov 28;352(9142):1731-8 PubMed

BMC Genomics. 2014 Feb 07;15:110 PubMed

Leukemia. 2000 Aug;14(8):1419-25 PubMed

Blood. 1994 Apr 15;83(8):2238-47 PubMed

J Clin Oncol. 2005 Nov 1;23(31):7942-50 PubMed

J Clin Oncol. 2016 Aug 1;34(22):2591-601 PubMed

BMC Genomics. 2016 Nov 4;17 (1):876 PubMed

Blood. 2004 May 15;103(10):3798-804 PubMed

Blood. 2015 Aug 20;126(8):1045-7 PubMed

CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 PubMed

J Clin Oncol. 2009 Nov 1;27(31):5168-74 PubMed

Blood. 2015 May 28;125(22):3501-8 PubMed

Bone Marrow Transplant. 2017 Jul;52(7):962-968 PubMed

N Engl J Med. 2006 Jan 12;354(2):166-78 PubMed

Nat Commun. 2013;4:2333 PubMed

Methods Mol Biol. 2012;840:197-228 PubMed

Blood. 2009 Apr 30;113(18):4153-62 PubMed

Blood. 2010 Apr 22;115(16):3206-14 PubMed

Haematologica. 2012 Oct;97(10):1582-93 PubMed

Leukemia. 2000 Aug;14(8):1426-35 PubMed

Leukemia. 2003 Aug;17(8):1573-82 PubMed

Blood. 2012 Nov 22;120(22):4407-17 PubMed

Curr Top Microbiol Immunol. 1999;246:205-13; discussion 214-5 PubMed

Blood. 2015 Jun 25;125(26):3996-4009 PubMed

Leukemia. 2003 Dec;17(12):2318-57 PubMed

J Mol Diagn. 2016 Jul;18(4):494-506 PubMed

Front Immunol. 2014 Feb 05;5:22 PubMed

BMC Genomics. 2014 May 28;15:409 PubMed

N Engl J Med. 2008 Aug 7;359(6):575-83 PubMed

Leukemia. 2013 Mar;27(3):635-41 PubMed

Blood. 2003 Jun 15;101(12):4695-700 PubMed

Bone Marrow Transplant. 2003 Oct;32(8):849-51 PubMed

Leukemia. 2004 Apr;18(4):884-6 PubMed

Br J Haematol. 2017 Jan;176(2):248-257 PubMed

Clin Cancer Res. 2014 Sep 1;20(17):4540-8 PubMed

Leukemia. 2002 Aug;16(8):1432-6 PubMed

Leukemia. 2003 Nov;17(11):2149-56 PubMed

J Immunol. 2017 May 15;198(10 ):3765-3774 PubMed

Blood. 2000 Feb 1;95(3):790-4 PubMed

Cytometry. 1999 Aug 15;38(4):139-52 PubMed

J Clin Oncol. 2014 Jan 20;32(3):174-84 PubMed

Nucleic Acids Res. 2012 Jan;40(1):e3 PubMed

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS